Brief introduction of Shanghai Xinxianfeng Pharmaceutical Co., Ltd.

Shanghai Pharmaceutical Group Co., Ltd., which was successfully listed after merger and capital injection, manages Shanghai Xinya Pharmaceutical Co., Ltd. and Shanghai Xinxianfeng Pharmaceutical Co., Ltd., which organically integrates the antibiotic business of Xinya Pharmaceutical Co., Ltd. and Xinxianfeng Pharmaceutical Co., Ltd. and becomes an indispensable part of the "whole industrial chain" of new drugs. Looking back on the history of Xinya and New Pioneer, countless China firsts were born under their feet: the earliest national medicine enterprise in China, the cradle of antibiotics in China, the first penicillin in China, and the first ANDA…… in China ... Today, the newly applied antibiotic professional platform has become one of the largest antibiotic pharmaceutical enterprises in China, and its three brands "Yazi", "Sanhua" and "Four Stars" cover all categories of anti-infective drugs. Ceftriaxone, cefotaxime, cefoperazone, cefotiam and cefazolin are the top three products in the domestic market, with a market share of over 20%.

As the first brand product to enter the China market, Ceftian, a "four-star brand", has the advantage of independent pricing, with a market share of over 35%. The exclusive variety Fengkesong (amphotericin B liposome) fills the domestic blank of liposome technology. More than ten kinds of products, such as ceftriaxone, fengkesong and cefazolin, won the title of famous brand products in Shanghai. The raw material drug cloxacillin and its preparation products, such as Fengtailing (piperacillin and tazobactam), ceftriaxone, cefotaxime and cefazolin, have been successfully registered in Japan, Hong Kong and other four countries and regions.

As a high-tech enterprise in Shanghai, the company adheres to the business philosophy of "quality creates value, innovation creates the future" and takes "science and technology promotes enterprises" as its development purpose, and constantly creates value for society, shareholders, customers, enterprises and employees. The company takes anti-infective drugs as the main development direction, actively expands the field of anti-tumor drugs and constantly makes new breakthroughs in scientific research and innovation. The company's new drug R&D center is the Shanghai-level enterprise technology center, which applied for the national invention patent 18. The number of new products approved by SFDA ranks first in Shanghai, and many heavyweight new products such as ceftizoxime, ceftizoxime, cefotetan and meropenem have been launched one after another. It has also undertaken three special projects for the creation of new drugs by the Ministry of Science and Technology.

Looking forward to the future, under the background that Shanghai Xinya Pharmaceutical Co., Ltd. is building an industrial park and reorganizing new drugs, Shanghai Xinya Pharmaceutical Co., Ltd. and Shanghai Xinxianfeng Pharmaceutical Co., Ltd. follow the principle of new drug development, combine the development strategy of new drugs, take Shanghai Xinya Pharmaceutical Co., Ltd. as the main platform, integrate the high-quality pharmaceutical assets of the antibiotic business sector, and become legal entities with clear corporate governance structure, reasonable main business, strong enterprise competitiveness and meeting the requirements of listed companies, and develop into new drug core enterprises.